Please assess the completion status of the following clinical trial:

Trial Title: Shanghai Registry of Acute Coronary Events

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients admitted to the hospital with acute coronary syndrome and received medical or interventional treatment~Exclusion Criteria:~* non ACS patients;~* complicated with other lethal disease~* predicted life span less than 12 months~* known allergy history to any anti-platelet or anti-thrombin medicine~* unconscious at the time of arrival at the hospital

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
- 2 (Type: None): patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
- 3 (Type: None): patients with non-ST-elevation ACS treated by immediate PCI
- 4 (Type: None): patients with non ST-elevation ACS treated by elective PCI
- 5 (Type: None): STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.
- 6 (Type: None): STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).

Based on this trial design, predict the completion outcome and termination type (if applicable).